Compare FTAI Aviation Ltd (FTAI) vs Moderna, Inc. (MRNA) Price & Performance

FTAI Aviation Ltd. (FTAI) trades at $199.72, down 3.15% on the day, with technical indicators signaling a bearish trend. The company reported strong revenue growth to $2.51B in 2025 and a net income margin near 19%, but has missed earnings expectations for three consecutive quarters. Recent strategic moves include a collaboration for Boeing 737-800 freighters and a major credit facility expansion to over $2 billion, highlighting its focus on aerospace services and the emerging data center power segment.

The outlook is mixed. Strong analyst consensus (18 Buy ratings) and robust profitability metrics like a 226.91% ROE support a bullish long-term view, driven by aerospace growth and data center innovation. However, near-term risks include consistent earnings misses, a high P/E ratio of 42.59, and negative operating cash flow, which could pressure the stock if execution falters or macro conditions worsen.

Moderna (MRNA) trades at $64.11, down 4.94% over 24 hours, with a bullish technical outlook but mixed fundamentals. The company reported a net loss of -$2.82B in 2025 despite beating EPS estimates in recent quarters. Recent news highlights progress in oncology trials and an EU RSV vaccine contract, fueling investor optimism about pipeline expansion beyond COVID-19 vaccines.

Outlook: Long-term growth depends on successful pipeline commercialization, but high cash burn and negative margins pose risks. Analyst consensus is cautious with a $49 price target, suggesting 23.6% downside. Investors should weigh clinical successes against persistent profitability challenges.